The Chemours Co. Provides Update on Full-Year 2022 Guidance
The Chemours Co. provided an update on its full-year 2022 guidance, announcing that adjusted EBITDA for 2022 is now expected to be between $1,400 million and $1,450 million–a midpoint approximately 7% below the midpoint of the prior guidance range, but about 9% above the prior year. Chemours will announce third-quarter 2022 financial results after market close on October 25, 2022.
Changes to the Titanium Technologies segment (TT) outlook drove the change in the company’s full-year guidance. The company stated that it now anticipates total company free cash flow of greater than $575 million, inclusive of actions taken to reduce full-year capital expenditures from $400 million to approximately $350 million, while continuing to invest in growth and sustainability initiatives.